Growth potential Seegene demonstrates a strong revenue base with growing half-year results and expanding international exposure, suggesting opportunities to expand distribution, co-marketing, and regional partnerships beyond Korea leveraging existing overseas entities.

AMR expansion The launch of the Allplex MDRO and upcoming MRSA assays indicate a strategic shift toward antimicrobial resistance testing, presenting sales opportunities for hospitals, reference labs, and public health programs needing comprehensive AMR panels and integrated workflows.

Syndromic testing The new syndromic PCR approach for reproductive tract infections plus STI/HPV panels creates cross-sell potential to laboratories and clinics seeking broad, rapid diagnostic coverage with single‑visit testing workflows.

Automation and data Investment in automated PCR workflows (CURECA) and real-time analytics (STAgora) signals a demand for scalable, data-driven diagnostics; sales plays can emphasize integrated hardware-software solutions and service contracts for high-throughput labs.

Platform shift Moving from reagents and instruments to a platform ecosystem opens upsell opportunities for upgrade paths, consumables, and services across global customers, including distributors like Eurobio Scientific with proven revenue potential.